G390Supervision of chemotherapy for induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation (maximum of 1 per induction phase or myeloablative therapy); and/or supervision of biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion (maximum of 1 per infusion); and/or supervision of bispecific antibody infusion, during initial dosing phase, where there is a high risk of cytokine release syndrome (maximum of 3 per initial dosing phase)
DIAGNOSTIC AND THERAPEUTIC PROCEDURES · INJECTIONS OR INFUSIONS
$262.40G390 identifies the Ontario insured service described as “Supervision of chemotherapy for induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation (maximum of 1 per induction phase or myeloablative therapy); and/or supervision of biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion (maximum of 1 per infusion); and/or supervision of bispecific antibody infusion, during initial dosing phase, where there is a high risk of cytokine release syndrome (maximum of 3 per initial dosing phase).” The listed fee and rules are reference data; the clinical record must support the service actually performed.
Before using this code
Confirm the current Ministry publication, the patient and provider context, the date of service, and documentation supporting the claim. A searchable reference does not establish eligibility or guarantee payment.